#1 Clinical Trials Search in Europe

Lutetium (177Lu)-Neobomb1

Lutetium (177Lu)-Neobomb1, also known as [177Lu]-NeoB, is an innovative radiopharmaceutical being investigated in clinical trials for the treatment of advanced solid tumors. This article explores the ongoing research into this promising drug, focusing on its potential applications in breast cancer, prostate cancer, and other solid tumors that overexpress gastrin-releasing peptide receptors (GRPR). We’ll discuss the key aspects of these trials, including their objectives, patient eligibility criteria, and potential benefits for patients with limited treatment options.

Table of Contents

What is LUTETIUM (177LU)-NEOBOMB1?

LUTETIUM (177LU)-NEOBOMB1, also known as [177Lu]-NeoB, is an innovative radiopharmaceutical drug currently being studied for the treatment of advanced solid tumors[1]. This medication combines a radioactive isotope (Lutetium-177) with a targeting molecule (NEOBOMB1) designed to seek out specific receptors on cancer cells[2].

How Does It Work?

The drug works through a mechanism called targeted radionuclide therapy. Here’s a simplified explanation of how it functions:

  1. The NEOBOMB1 part of the drug targets a specific protein called gastrin-releasing peptide receptor (GRPR), which is overexpressed in certain types of cancer cells[2].
  2. Once the drug binds to these receptors, the radioactive Lutetium-177 delivers localized radiation to the tumor cells.
  3. This targeted approach aims to destroy cancer cells while minimizing damage to healthy tissues[1].

What Conditions Does It Target?

LUTETIUM (177LU)-NEOBOMB1 is being investigated for various types of advanced solid tumors, including:

  • Breast cancer: Specifically, hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer[1].
  • Prostate cancer
  • Lung cancer
  • Gastrointestinal stromal tumors (GIST)
  • Glioblastoma multiforme (GBM): A type of brain cancer[2].

Current Clinical Trials

Two significant clinical trials are currently underway to evaluate the safety and efficacy of LUTETIUM (177LU)-NEOBOMB1:

  1. A Phase I/II trial combining [177Lu]-NeoB with capecitabine (a chemotherapy drug) for patients with advanced breast cancer[1].
  2. A Phase I/IIa trial called NeoRay, studying [177Lu]-NeoB in patients with various advanced solid tumors[2].

These trials aim to determine the optimal dosage, assess the drug’s anti-tumor activity, and evaluate its safety profile.

How Is It Administered?

LUTETIUM (177LU)-NEOBOMB1 is administered as a solution for intravenous infusion. This means it’s given directly into the bloodstream through a vein[1][2]. The exact dosing schedule and frequency may vary depending on the specific clinical trial protocol.

Who Is Eligible for Treatment?

Eligibility criteria for treatment with LUTETIUM (177LU)-NEOBOMB1 may include:

  • Adult patients (18 years or older) with advanced solid tumors
  • Tumors that overexpress the gastrin-releasing peptide receptor (GRPR)
  • Measurable disease according to specific imaging criteria
  • Previous treatment history (varies depending on the specific cancer type and trial)
  • Adequate organ function and overall health status[1][2]

It’s important to note that specific eligibility criteria may vary between different clinical trials and cancer types.

Potential Side Effects

As with any medical treatment, LUTETIUM (177LU)-NEOBOMB1 may cause side effects. The ongoing clinical trials are carefully monitoring for:

  • Changes in blood cell counts
  • Effects on kidney and liver function
  • Cardiac (heart) effects
  • Other potential adverse events[1][2]

The full range of potential side effects is still being studied as part of the clinical trials.

Future Prospects

LUTETIUM (177LU)-NEOBOMB1 represents an exciting development in the field of targeted cancer therapy. If proven safe and effective in clinical trials, it could offer a new treatment option for patients with advanced solid tumors, particularly those who have not responded to or are not eligible for standard therapies[1][2].

As research continues, we may gain more insights into its effectiveness, optimal use, and potential combinations with other cancer treatments. Patients interested in this treatment should discuss with their oncologists whether participating in a clinical trial might be appropriate for their specific situation.

Aspect Details
Drug Name Lutetium (177Lu)-Neobomb1 ([177Lu]-NeoB)
Drug Type Radiopharmaceutical
Administration Intravenous infusion
Target Cancers Advanced solid tumors overexpressing GRPR (e.g., breast, prostate, GIST, GBM)
Trial Phases Phase I/II
Main Objectives Determine safe dose, evaluate anti-tumor activity, assess safety and tolerability
Key Eligibility Criteria Adult patients, advanced solid tumors, GRPR overexpression, [68Ga]-NeoB uptake on imaging
Combination Therapy Studied with capecitabine in some trials
Endpoints Dose-limiting toxicities, objective response rate, pharmacokinetics, biodistribution

FAQ

  • What is Lutetium (177Lu)-Neobomb1? Lutetium (177Lu)-Neobomb1, also known as [177Lu]-NeoB, is a radiopharmaceutical being studied for the treatment of advanced solid tumors. It combines a radioactive isotope (Lutetium-177) with a targeting molecule that binds to gastrin-releasing peptide receptors (GRPR) found on certain cancer cells.
  • What types of cancer are being studied with this drug? The clinical trials are focusing on several types of advanced solid tumors, including breast cancer, prostate cancer, gastrointestinal stromal tumors (GIST), and glioblastoma multiforme (GBM). The drug is particularly being studied in tumors that overexpress gastrin-releasing peptide receptors (GRPR).
  • How is Lutetium (177Lu)-Neobomb1 administered? Lutetium (177Lu)-Neobomb1 is administered as a solution for infusion, which means it is given intravenously (through a vein) to patients.
  • What are the main objectives of these clinical trials? The main objectives of these trials include determining the safe and effective dose of the drug, evaluating its anti-tumor activity, assessing its safety and tolerability, and studying how the drug is distributed and processed in the body (pharmacokinetics and biodistribution).
  • Who is eligible to participate in these clinical trials? Eligibility varies depending on the specific trial and phase, but generally includes adult patients with advanced solid tumors that overexpress GRPR and show uptake of a diagnostic version of the drug ([68Ga]-NeoB) on imaging scans. Patients must also have exhausted standard treatment options or have no suitable alternatives available.

Ongoing Clinical Trials on Lutetium (177Lu)-Neobomb1

  • Study of [177Lu]Lu-NeoB and Capecitabine for Patients with Advanced Breast Cancer Resistant to Hormone Therapy

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Portugal Spain

  • Study on the Safety and Effects of [177Lu]-NeoB in Patients with Advanced Solid Tumors Overexpressing GRPR

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France The Netherlands Spain

Glossary

  • Radiopharmaceutical: A drug that contains a radioactive substance used for diagnosing or treating diseases, especially cancer.
  • Gastrin-releasing peptide receptor (GRPR): A protein found on the surface of certain cells, including some cancer cells, that can be targeted by specific drugs or imaging agents.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Estrogen receptor-positive (ER+): A type of breast cancer that grows in response to the hormone estrogen.
  • HER2-negative: Breast cancer cells that do not have high levels of a protein called HER2 on their surface.
  • CDK4/6 inhibitor: A type of drug that blocks specific proteins involved in cell division, used in the treatment of some breast cancers.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent increasing the dose or require a dose reduction.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Biodistribution: The pattern of distribution of a substance throughout the body's tissues and organs.

References

  1. http://clinicaltrials.eu/trial/study-of-177lulu-neob-and-capecitabine-for-patients-with-advanced-breast-cancer-resistant-to-hormone-therapy/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-177lu-neob-in-patients-with-advanced-solid-tumors-overexpressing-grpr/